

1 **Efficacy of remdesivir-containing therapy in hospitalized COVID-19**  
2 **patients: a prospective clinical experience**

3

4

5 Alessandro Russo<sup>1</sup>, Erica Binetti<sup>2</sup>, Cristian Borrazzo<sup>2</sup>, Elio Gentilini Cacciola<sup>2</sup>, Luigi Battistini<sup>2</sup>,  
6 Giancarlo Ceccarelli<sup>2</sup>, Claudio Maria Mastroianni<sup>2</sup>, Gabriella d'Ettore<sup>2</sup>

7

8 <sup>1</sup> Infectious and Tropical Disease Unit, Department of Medical and Surgical Sciences, "Magna Graecia"  
9 University of Catanzaro, Italy

10 <sup>2</sup> Policlinico "Umberto I", Department of Public Health and Infectious Diseases, "Sapienza" University of Rome,  
11 Italy

12

13

14 **Running head:** Remdesivir for treatment of COVID-19

15

16 **Word count:** 2201

17

18

19

20

21

22

23

24

25 **Corresponding author**

26 Prof. Alessandro Russo

27 Infectious and Tropical Disease Unit, Department of Medical and Surgical Sciences

28 Viale Europa, 88100, "Magna Graecia" University of Catanzaro, Italy

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

29 Email: [a.russo@unicz.it](mailto:a.russo@unicz.it); [alessandro.russo1982@gmail.com](mailto:alessandro.russo1982@gmail.com)

30 **ABSTRACT**

31 **Objectives:** remdesivir is currently approved for the treatment of COVID-19. The recommendation  
32 for using remdesivir in COVID-19 was based on the *in vitro* and *in vivo* activity of this drug against  
33 SARS-CoV-2.

34 **Methods:** this was a prospective, observational study conducted on a large population of patients  
35 hospitalized for COVID-19. The primary endpoint of the study was to evaluate the impact of  
36 remdesivir-containing therapy on 30-day mortality; secondary endpoint was the impact of  
37 remdesivir-containing therapy on the need of high flow oxygen therapy (HFNC) or non-invasive  
38 ventilation (NIV) or mechanical ventilation. Data were analyzed after propensity score matching.

39 **Results:** 407 patients with SARS-CoV-2 pneumonia were consecutively enrolled. Out of these, 294  
40 (72.2%) and 113 (27.8%) were respectively treated or not with remdesivir. Overall, 61 (14.9%)  
41 patients were treated during hospitalization with non-invasive or mechanical ventilation, while a 30-  
42 day mortality was observed in 21 (5.2%) patients with a global in-hospital mortality of 11%. Cox  
43 regression analysis, after propensity score matching, showed that therapies, including remdesivir-  
44 containing therapy, were not statistically associated with 30-day survival or mortality, while need of  
45 HFNC/NIV (HR 17.921, CI95% 0.954-336.73, p=0.044) and mechanical ventilation (HR 3.9,  
46 CI95% 5.36-16.2, p=0.003) resulted independently associated with 30-day mortality. Finally,  
47 therapies including or not remdesivir were not independently associated with a lower or higher risk  
48 of HFNC/NIV or mechanical ventilation.

49 **Conclusions:** this real-life experience about the remdesivir use in hospitalized patients with  
50 COVID-19 was not associated with significant increase in rates of survival or reduced use of  
51 HFNC/NIV or mechanical ventilation, compared to patients treated with other therapies not  
52 including remdesivir.

53

54 **Key words:** remdesivir; COVID-19; pneumonia; non-invasive ventilation; mechanical ventilation.

55

56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81

## INTRODUCTION

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is identified as the cause of an outbreak of respiratory illness, evolving in a pandemic. The virus causes respiratory illness and can rapidly spread from person to person; then, in a large number of patients this virus causes coronavirus diseases (COVID-19) characterized by pneumonia, severe acute respiratory syndrome, kidney failure, and a significant rate of mortality [1-2-3].

To date, treatment of critically ill infected patients is primarily supportive with a robust evidence reported in literature about the use of steroids, especially dexamethasone, in lowering mortality especially in critically ill patients [4]; some important evidence suggests also the role of low-molecular-weight heparin (LMWH) to reduce in-hospital mortality [5].

As a matter of fact, only remdesivir was currently approved for the treatment of COVID-19. The recommendation for using remdesivir as treatment of COVID-19 is based on the *in vitro* and *in vivo* activity of remdesivir against SARS-CoV-2 [6]. Moreover, remdesivir showed an acceptable safety profile and exhibits *in vivo* prophylactic and therapeutic efficacy against SARS-CoV-2 infection [7].

According to randomized clinical trials, its administration might shorten the time to recovery and reduce severity of infection in adults hospitalized with COVID-19 [8]. However, there are still many ongoing clinical trials and more evidence is needed to confirm the efficacy of remdesivir in treating patients with COVID-19 at different stages of severity.

Aim of our study was to evaluate in a real-life, prospective, experience the impact of remdesivir on 30-day mortality and the need of non-invasive or invasive ventilation in hospitalized patients with SARS-CoV-2 pneumonia.

82

83

## 84 **RESULTS**

85         During the study period 407 patients with SARS-CoV-2 pneumonia were consecutively  
86 enrolled. Out of these, 294 (72.2%) and 113 (27.8%) were respectively treated or not with  
87 remdesivir. Overall, 61 (14.9%) patients were treated during hospitalization with non-invasive or  
88 mechanical ventilation, while a 30-day mortality was observed in 21 (5.2%) patients, with a global  
89 in-hospital mortality of 11%.

90         In **Table 1** is reported univariate analysis about demographics and clinical characteristics of  
91 COVID-19 patients treated or not with remdesivir. Statistically significant differences were  
92 observed in remdesivir group about male sex (80% Vs 62%,  $p<0.001$ ), fever (79% Vs 50%,  
93  $p<0.001$ ), cough (50% Vs 29%,  $p<0.001$ ), dyspnea (57% Vs 37%,  $p<0.001$ ), compared to patients  
94 not treated with remdesivir. No statistically significant differences were observed in the remdesivir  
95 group about age (63.2 Vs 62.5 years,  $p=0.717$ ), length of hospital stay (15.02 Vs 16.06 days,  
96  $p=0.487$ ), and days to nasopharyngeal swab negativization (22.07 vs 24.77 days,  $p=0.378$ ). Finally,  
97 no differences were observed about bacterial co-infection (20% Vs 21%,  $p=0.928$ ) and 30-day  
98 mortality (4% Vs 6%,  $p=0.411$ ).

99         Other treatments used in COVID-19 patients were reported in **Table 2**. Comparison between  
100 patients treated or not with remdesivir showed that steroids (93% Vs 81%,  $p<0.001$ ), LMWH (93%  
101 Vs 52%,  $p<0.001$ ) were more frequently prescribed in remdesivir group. Antibiotic therapy (58%  
102 Vs 27%,  $p<0.001$ ) was more frequently prescribed for patients not treated with remdesivir, while no  
103 differences were reported about the use of HFNC/NIV or mechanical ventilation in the 2 study  
104 groups.

105         In **supplementary Table 1** is reported univariate analysis after propensity score matching to  
106 evaluate the impact of remdesivir-containing regimen on study population (**for reviewers'**  
107 **information only**). **Figure 1** showed Kaplan Meier curves about 30-day survival in patients treated

108 or not with remdesivir before (p=0.24) and after (p=0.07) propensity score matching, reporting no  
109 differences between the 2 study groups. Standardized differences before and after propensity score  
110 matching were reported in **supplementary Figure 1 (for reviewers' information only)**.

111 Multivariate Cox regression analysis about 30-day mortality after propensity score matching  
112 was reported in **Table 3**. Comorbidities and therapies, including remdesivir-containing therapy,  
113 were not statistically associated with 30-day survival or mortality. Instead, HFNC/NIV (HR 17.921,  
114 CI95% 0.954-336.73, p=0.044) and mechanical ventilation (HR 3.9, CI95% 5.36-16.2, p=0.003)  
115 resulted independently associated with 30-day mortality

116 Finally, multivariate Cox regression analysis about need of non-invasive or invasive  
117 ventilation was analyzed after propensity score matching (see **Table 4**). Data showed that  
118 comorbidities and therapies, including remdesivir-containing regimen, were not independently  
119 associated with a lower or higher risk of HFNC/NIV or mechanical ventilation.

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

## 135 **DISCUSSION**

136 This prospective clinical study reported a real-life experience about the use of remdesivir in  
137 a large population of consecutively hospitalized patients with COVID-19. Our data, also after  
138 propensity score matching, showed that remdesivir-containing regimen was not associated with 30-  
139 day survival compared to patients treated with other therapies not including remdesivir. Moreover,  
140 remdesivir-containing regimen was not independently related to progression or not to HFNC/NIV  
141 or mechanical ventilation.

142 In Italy, remdesivir was specifically licensed for the treatment of COVID-19 in hospitalized  
143 patients with pneumonia, requiring oxygen therapy but not treated with HFNC/NIV or mechanical  
144 ventilation at time of remdesivir prescription [9].

145 Different data were worldwide reported about the efficacy of remdesivir, taking in account  
146 different outcomes. Remdesivir treatment was associated with significantly higher recovery rates  
147 and lower mortality, compared to standard-of-care treatment without remdesivir in patients with  
148 severe COVID-19 [10]. In this study, significantly lower mortality was observed in those treated  
149 with remdesivir (7.6%) compared with the non-remdesivir-cohort patients (12.5%). Conversely,  
150 data from Solidarity trial, conducted in 30 countries [11], showed no decrease of in-hospital  
151 mortality in patients treated with remdesivir, with the important limitation that other outcomes,  
152 clinical improvement and adverse events, were non carefully evaluated.

153 Some important meta-analysis showed that COVID-19 patients receiving remdesivir had  
154 significantly higher rates of recovery and hospital discharge with lower rates of developing serious  
155 adverse events compared to patients receiving standard of care/placebo [12-13]. However, these  
156 analyses confirmed that no significant differences were observed about clinical improvement and  
157 rate of mortality during hospitalization. Specifically, mortality was the main outcome reported in all  
158 included studies, and none of the studies showed significant decrease of mortality also if they were  
159 not adequately powered for mortality outcome [12].

160 Wang et al. [14] reported the first double blinded, randomized, clinical trial in which were  
161 evaluated patients with an interval from symptoms onset to enrollment of 12 days or less. No  
162 differences in mortality were recorded in the 2 arms, also if authors highlighted a possible trend  
163 towards clinical benefit in remdesivir group. Of importance, a large number of patients in this study  
164 were treated also with steroids (65% of patients who received remdesivir and 68% of patients in  
165 placebo arm) which may have confounded the results and the conclusions. A strength of our study,  
166 with the limit of the non-randomized cohort, was to weight all the possible therapeutic confounders,  
167 comprising the use of steroids and LMWH.

168 Beigel et al. [8] randomized 1062 patients, hospitalized with COVID-19 and evidence of  
169 pneumonia, to remdesivir or placebo. The study demonstrated that remdesivir was superior to  
170 placebo in shortening the time to recovery in hospitalized COVID-19 patients with a trend towards  
171 survival benefit at day 29 without statistically significant differences. Of interest, authors reported a  
172 beneficial effect of remdesivir in severe COVID-19 patients but not requiring mechanical  
173 ventilation at enrollment; they suggested to start remdesivir early in the disease course.

174 Finally, in another randomized, clinical trial [15] in patients with moderate COVID-19 (no  
175 oxygen requirements, also if about 15% of patients required oxygen at time of enrollment) authors  
176 randomized 596 patients in 1:1:1 ratio to receive a 5-day course of remdesivir, a 10- day course of  
177 remdesivir, or standard of care therapy. In this study patients randomized to 5-day, but not 10- day  
178 treatment duration, showed a statistically significant difference in clinical status. A subgroup  
179 analysis excluding patients who required oxygen at baseline showed a significant difference  
180 favouring remdesivir over standard care.

181 Our study has some limitations. First, considering the monocentric design these results  
182 might be affected by local practice in the management of COVID-19; second, although criteria for  
183 HFNC/NIV or mechanical ventilation were based on the degree of respiratory impairment, elderly  
184 critically ill patients with ultimately fatal diseases were probably excluded from non-  
185 invasive/invasive ventilation, modifying the interpretation of some interventions. Second, in this

186 analysis were evaluated all consecutively, hospitalized patients independently from COVID-19  
187 severity, as demonstrated also by the low mortality (6% of remdesivir group Vs 4% of patients not  
188 treated with remdesivir). Finally, the analysis on the beneficial effects of treatments should be  
189 interpreted cautiously, because it was not conducted on randomized groups and might therefore be  
190 affected by several measured and unmeasured confounding factors. However, the comparison of  
191 remdesivir-treated patients with non-remdesivir-treated patients was based on a robust statistical  
192 methodology, appropriate for non-randomized cohort studies about therapy.

193 In conclusion, in our real-life experience about the remdesivir use in hospitalized patients  
194 with COVID-19 was not associated with significant increase in rates of survival or reduced use of  
195 HFNC/NIV or mechanical ventilation, compared to patients treated with other therapies not  
196 including remdesivir. These results suggest the need of more RCTs to evaluate the role of  
197 remdesivir in COVID-19 patients at different stages of disease or in combination with other drugs  
198 [16]. However, considering its safety profile and the lack of alternative drugs, remdesivir should be  
199 continued to be administered for patients with COVID-19.

200

201

202

203

204

205

206

207

208

209

210

211



## 212 **METHODS**

### 213 *Study Design and Data Collection*

214 This prospective, observational study included, from October 2020 to February 2021,  
215 patients admitted to University Hospital of Rome ‘‘Policlinico Umberto I’’, in Italy. Inclusion  
216 criteria were: 1) positive SARS-CoV-2 real-time polymerase chain reaction test or an antigenic test  
217 on a nasopharyngeal swab; 2) pneumonia diagnosed either by CT thorax or chest x-ray; 3) need of  
218 hospitalization. Patients who required high flow oxygen therapy (HFNC) or non-invasive  
219 ventilation (NIV) or mechanical ventilation at time of hospitalization were excluded from this  
220 analysis.

221 All patients were evaluated in a dedicated Emergency Department by a dedicated staff of  
222 infectious diseases specialists that identified patients with SARS-CoV-2 pneumonia as soon as they  
223 arrived at the hospital, followed the patients during the hospital stay, and collected all data  
224 prospectively without interfering with the therapeutic decisions. This observational study was  
225 conducted according to the principles stated in the Declaration of Helsinki, and it conforms to  
226 standards currently applied in our country. The study was approved by the local EC. The patient’s  
227 informed consent was obtained.

228 Data were extracted from the medical records of patients and from hospital computerized  
229 databases. The following data were collected: demographics, clinical and laboratory findings,  
230 comorbidities, Charlson comorbidity index, microbiologic data, date of COVID-19 diagnosis,  
231 radiological characteristics of the pneumonia, therapies, concomitant infections, duration of  
232 mechanical ventilation, time of nasopharyngeal swab negativity, need of oxygen or ventilation  
233 support during the hospital stay, length of ICU stay, length of hospital stay. Development of  
234 moderate to severe ARDS was defined as the acute onset of hypoxemia, manifestations of  
235 pneumonia on chest computed tomography imaging of a noncardiac origin, and a PaO<sub>2</sub>/FiO<sub>2</sub> ratio  
236 of less than 200 mmHg according to the Berlin Definition [17].

237 Remdesivir was administrated, after written informed consent, to patients with the following  
238 characteristics: pneumonia, less than 10 days from the onset of symptoms, no need for HFNC or  
239 NIV or mechanical ventilation, alanine aminotransferase no more than 5 times the upper limit of the  
240 reference range, estimated glomerular filtration rate (eGFR) greater than 30 mL/minute. A 5-day  
241 regimen was prescribed in all cases. Patients without these criteria were not eligible for remdesivir  
242 treatment.

243 All patients were followed-up until discharge or death.

244

### 245 **Endpoints and Statistical analysis**

246 The primary endpoint of the study was to evaluate the impact of remdesivir-containing  
247 therapy on 30-day mortality in hospitalized patients with SARS-CoV2 pneumonia. Secondary  
248 endpoint was the impact of remdesivir-containing therapy on the need of NIV or mechanical  
249 ventilation.

250 To reduce the impact of treatment-selection bias in the estimation of treatment effects,  
251 propensity score matching was conducted. Variables were selected for inclusion in the propensity  
252 score based on potential impact on receipt of remdesivir and association with mortality [18]. The  
253 variables included were steroids, antibiotics (excluding macrolides), age, gender, and the use of  
254 LMWH during hospital admission. A propensity score density plot and Love plot were generated to  
255 examine the balance of propensity score and covariate distribution between the two groups (see  
256 **supplementary Figure 1**).

257 To evaluate demographic factors, Welch's t tests assuming unequal variances were used for  
258 continuous independent variables, while Pearson Chi-square or Fisher's Exact Test when  
259 appropriate were used for categorical variables. Welch's analysis of variance (ANOVA) was used  
260 to assess group differences for continuous outcome. Welch's t-tests assuming unequal variances  
261 were used for post-hoc comparisons.

262 All tests will be two-tailed, and a p-value of  $<0.05$  were considered statistically significant.  
263 Results were expressed as the mean with standard deviation ( $\pm$ SD) for continuous normally  
264 distributed variables and as a count (n) and percentage (%) for categorical variables. Multivariate  
265 analysis was used to identify independent predictors of 30-day mortality and need of NIV or  
266 mechanical ventilation. Matched bivariate analyses were conducted using a conditional logistic  
267 regression model, incorporating all variables found to be significant in the Univariate analysis ( $p <$   
268  $0.05$ ) with a stepwise method. Matched multivariate models was constructed using Cox  
269 proportional hazards (HRs) regression if appropriate, accounting for clustering on matched pairs.  
270 The final selected model was tested for confounding. In addition, 95% confidence intervals were  
271 calculated for HR. Survival was analyzed by Kaplan-Meier curves. All data were analyzed using a  
272 commercially available statistical software package (SPSS Statistics for Mac, 22.0; IBM Corp.,  
273 Armonk, NY).

274

275

276

## 277 **ACKNOWLEDGEMENT**

278 **Conflict of interest:** none to declare.

279 **Funding:** none.

280 **Transparency declarations:** none to declare.

281

282

283

284

285

286

287

288

289

290

291

292  
293  
294  
295  
296  
297  
298  
299  
300

**Table 1.** Univariate analysis about demographics and clinical characteristics of COVID-19 patients treated or not with remdesivir

Variables	No remdesivir N = 113 (%)	Remdesivir N = 294 (%)	P value
Male sex	70 (62%)	250 (80%)	<0.001
Age, year, mean ( $\pm$ SD)	62.5 ( $\pm$ 20)	63.2 ( $\pm$ 15.3)	0.717
Days from symptoms/positive nasopharyngeal swab to admission, mean ( $\pm$ SD)	4.5 ( $\pm$ 4.3)	5.3 ( $\pm$ 3.8)	0.084
Comorbidities	77 (68%)	213 (70%)	0.919
Cardiovascular disease	17 (15%)	33 (11%)	0.203
COPD	19 (17%)	31 (10%)	0.051
Chronic kidney disease	10 (9%)	18 (6%)	0.256
Liver cirrhosis	2 (2%)	12 (4%)	0.293
Diabetes mellitus	21 (19%)	53 (17%)	0.672
Solid lung cancer (primary or metastasis)	1 (1%)	3 (1%)	1.000
Fever	56 (50%)	246 (79%)	<0.001
Cough	33 (29%)	157 (50%)	<0.001
Dyspnea	42 (37%)	178 (57%)	<0.001
Gastrointestinal symptoms (diarrhea, abdominal discomfort, nausea, vomiting)	16 (14%)	58 (18%)	0.271
Fatigue	21 (19%)	57 (19%)	1.000
Pharyngodynia	6 (5%)	14 (5%)	1.000
Rhinitis	3 (3%)	15 (5%)	0.329
Arthralgia/Myalgia	13 (12%)	45 (14%)	0.460
Anosmia	3 (3%)	9 (3%)	1.000

Variables	No remdesivir N = 113 (%)	Remdesivir N = 294 (%)	P value
Conjunctivitis	0 (0%)	2 (1%)	0.397
Chest pain	5 (4%)	11 (3%)	0.655
Signs of overload (limb edema and/or pulmonary stasis)	4 (4%)	2 (1%)	0.647
Parenchymal thickening	72 (64%)	232 (74%)	0.046
Interstitial lung disease	16 (14%)	15 (5%)	<b>&lt;0.001</b>
Pleural effusion	20 (18%)	26 (9%)	<b>0.012</b>
Cardiomegaly	8 (7%)	16 (5%)	0.438
Bronchiectasis/ Emphysema	27 (24%)	50 (15%)	<b>0.032</b>
White Blood cells x10 <sup>3</sup> /uL, mean (±SD)	7.38 (± 3.59)	8.06 (± 5.99)	0.287
Neutrophils x10 <sup>3</sup> /uL, mean (±SD)	5.60 (± 3.61)	6.31 (± 5.31)	0.211
Lymphocytes x10 <sup>3</sup> /uL, mean (±SD)	1.18 (± 0.65)	1.12 (± 2.28)	0.769
Platelets x10 <sup>3</sup> /uL, mean (±SD)	247.66 (± 100.85)	218.47 (± 81.73)	<b>0.004</b>
D-dimer ng/mL, mean (±SD)	1365.71 (± 1456.18)	814.91 (± 766.45)	<b>&lt;0.001</b>
Ferritin ng/mL, mean (±SD)	692.35 (± 942.17)	645.02 (± 489.52)	0.591
Procalcitonin ng/mL, mean (±SD)	1.20 (± 6.4)	0.61 (± 3.73)	0.334
LDH mU/mL, mean (±SD)	288.46 (± 163.73)	302.37 (± 119.57)	0.3
CPK U/L, mean (±SD)	278.90 (± 1430.63)	149.47 (± 161.35)	0.170
Lactates mmol/L, mean (±SD)	1.57 (± 0.36)	1.33 (± 0.83)	0.328
C-reactive protein mg/dL, mean (±SD)	4.91 (± 6.61)	8.23 (± 21.13)	0.116
PaO <sub>2</sub> /FiO <sub>2</sub> , mean (±SD)	315.67 (± 117.14)	329.94 (± 98.36)	0.411
Aspartate Transaminase U/L, mean (±SD)	34.16 (± 47.76)	35.24 (± 27.41)	0.784
Alanine transaminase U/L, mean (±SD)	32.20 (± 28.42)	33.24 (± 28.84)	0.755
Bacterial co-infection	24 (21%)	65 (20%)	0.928
Days of hospitalization, mean (±SD)	16.06 (± 17.62)	15.02 (± 9.98)	0.487
Days to nasopharyngeal swab negativization, mean (±SD)	24.77 (± 17.1)	22.07 (± 13.77)	0.378
30-day mortality	4 (4%)	17 (6%)	0.411

**Legend.** COPD: chronic obstructive pulmonary disease; LDH: lactate dehydrogenase; CPK: ; creatine phosphokinase.

304  
305  
306  
307  
308  
309  
310  
311  
312

313 **Table 2.** Other treatments in COVID-19 patients treated or not with remdesivir

<b>Variables</b>	<b>No remdesivir N = 113 (%)</b>	<b>Remdesivir N = 294 (%)</b>	<b>P value</b>
Steroids	92 (81%)	289 (93%)	<b>&lt;0.001</b>
Antibiotics (excluding macrolides)	65 (58%)	83 (27%)	<b>&lt;0.001</b>
Macrolides	74 (65%)	146 (46%)	<b>&lt;0.001</b>
Low-molecular-weight heparin	59 (52%)	280 (93%)	<b>&lt;0.001</b>
Low-flow oxygen therapy / no need of oxygen therapy	89 (79%)	275 (87%)	<b>0.044</b>
HFNC/NIV	17 (15%)	33 (10%)	0.155
Mechanical ventilation	1 (1%)	10 (3%)	0.2

314 **Legend.** HFNC: high flow nasal cannula; NIV: non-invasive ventilation.

315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339

340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350

**Table 3.** Multivariate Cox regression analysis about 30-day mortality after propensity score matching

<b>Variables</b>	<b>HR</b>	<b>CI95%</b>	<b>P value</b>
Comorbidities	0.136	0.009-2.04	0.149
Chronic kidney disease	1.773	0.022-140.18	0.797
COPD	3.033	0.097-95.03	0.528
Bacterial co-infection	0.693	0.061-7.81	0.767
Low-molecular-weight heparin	0.169	0.013-2.17	0.173
Macrolides	23.056	0.273-19,8	0.165
Antibiotics (excluding macrolides)	1.512	0.18-12.67	0.703
Steroids	0.1	0.0-1.2	0.89
Low-flow oxygen therapy/no need of oxygen therapy	11.682	0.575-237.45	0.11
Remdesivir	0.87	0.12-1.17	0.18
HFNC/NIV	17.921	0.954-336.73	<b>0.044</b>
Mechanical ventilation	3.9	5.36-16.2	<b>0.003</b>

351 **Legend.** COPD: chronic obstructive pulmonary disease; HFNC: high flow nasal cannula; NIV: non-invasive  
352 ventilation.

353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366

367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377

**Table 4.** Multivariate Cox regression analysis about need of non-invasive or invasive ventilation after propensity score matching

<b>Variables</b>	<b>HR</b>	<b>IC</b>	<b>P value</b>
Comorbidities	0.1	0.09-1.4	0.149
Chronic kidney disease	1.8	0.24-4.2	0.797
COPD	1.03	0.068-15.64	0.528
Bacterial co-infection	0.7	0.1-1.81	0.767
Low-molecular-weight heparin	0.169	0.01-2.17	0.173
Macrolides	0.31	0.01-8.8	0.493
Antibiotics (excluding Macrolides)	1.51	0.18-12.67	0.703
Steroids	3.2	0.78-136.9	0.890
Remdesivir	1.03	0.68-15.6	0.737

378 **Legend.** COPD: chronic obstructive pulmonary disease.

379  
380  
  
381  
  
382  
  
383  
  
384  
  
385  
  
386  
  
387



388

389


390

391

392 **Figure 1.** Kaplan Meier curves about 30-day survival in patients treated or not with remdesivir  
393 before ( $p=0.24$ ) and after ( $p=0.07$ ) propensity score matching

394

395



396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413 **REFERENCES**

---

<sup>1</sup> <https://covid19.who.int>, Accessed on 27 April 2021.

<sup>2</sup> Russo A, Bellelli V, Ceccarelli G, Marincola Cattaneo F, Bianchi L, Pierro R, Russo R, Steffanina A, Pugliese F, Mastroianni CM, d'Ettore G, Sabetta F. 2020. Comparison between hospitalized patients affected or not by COVID-19 (RESILIENCY study). *Clin Infect Dis*. 2020 Nov 18:ciaa1745. doi: 10.1093/cid/ciaa1745. Epub ahead of print.

<sup>3</sup> Vistoli F, Furian L, Maggiore U, Caldara R, Cantaluppi V, Ferraresso M, Zaza G, Cardillo M, Biancofiore G, Menichetti F, Russo A, Turillazzi E, Di Paolo M, Grandaliano G, Boggi U; Italian National Kidney Transplantation Network; the Joint Committee of the Italian Society of Organ Transplantation and the Italian Society of Nephrology. 2020. COVID-19 and kidney transplantation: an Italian Survey and Consensus. *J Nephrol*. 33:667-680.

<sup>4</sup> RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. 2021. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med*. 384:693-704.

<sup>5</sup> Falcone M, Tiseo G, Barbieri G, Galfo V, Russo A, Viridis A, Forfori F, Corradi F, Guarracino F, Carrozzi L, Celi A, Santini M, Monzani F, De Marco S, Pistello M, Danesi R, Ghiadoni L, Farcomeni A, Menichetti F; Pisa COVID-19 Study Group. 2020. Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study. *Open Forum Infect Dis*. 7:ofaa563

<sup>6</sup> Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G. 2020. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res*. 30:269-271.

<sup>7</sup> Frediansyah A, Nainu F, Dhama K, Mudatsir M, Harapan H. Remdesivir and its antiviral activity against COVID-19: A systematic review. *Clin Epidemiol Glob Health*. 2021;9:123-127.

<sup>8</sup> Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, Hohmann E, Chu HY, Luetkemeyer A, Kline S, Lopez de Castilla D, Finberg RW, Dierberg K, Tapson V, Hsieh L, Patterson TF, Paredes R, Sweeney DA, Short WR, Touloumi G, Lye DC, Ohmagari N, Oh MD, Ruiz-Palacios GM, Benfield T, Fätkenheuer G, Kortepeter MG, Atmar RL, Creech CB, Lundgren J, Babiker AG, Pett S, Neaton JD, Burgess TH, Bonnett T, Green M, Makowski M, Osinusi A, Nayak S, Lane HC; ACTT-1 Study Group Members. 2020. Remdesivir for the Treatment of Covid-19 - Final Report. *N Engl J Med*. 383:1813-1826.

<sup>9</sup> <https://www.aifa.gov.it/-/procedura-di-richiesta-per-il-farmaco-veklury-remdesivir>. Accessed on 28 April 2021.

<sup>10</sup> Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, Wang S, Walunas TL, Swaminathan S, Slim J, Chin B, De Wit S, Ali SM, Soriano Viladomiu A, Robinson P, Gottlieb RL, Tsang TYO, Lee IH, Haubrich RH, Chokkalingam AP, Lin L, Zhong L, Bekele BN, Mera-Giler R, Gallant J, Smith LE, Osinusi AO, Brainard DM, Hu H, Phulpin C, Edgar H, Diaz-Cuervo H, Bernardino JI. 2020. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care. *Clin Infect Dis*. 2020 Jul 24:ciaa1041. doi: 10.1093/cid/ciaa1041. Epub ahead of print.

<sup>11</sup> WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP, Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP, Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM, Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J, García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D, Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N, Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-Montoya MC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, Rogers CA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO, Trelle S, Zaid H, Røttingen JA, Swaminathan S. 2021. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. *N Engl J Med*. 384:497-511.

---

<sup>12</sup> Al-Abdoun A, Bizanti A, Barbarawi M, Jabri A, Kumar A, Fashanu OE, Khan SU, Zhao D, Antar AAR, Michos ED. 2021. Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials. *Contemp Clin Trials*. 101:106272.

<sup>13</sup> Wilt TJ, Kaka AS, MacDonald R, Greer N, Obley A, Duan-Porter W. 2021. Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points. *Ann Intern Med*. 174:209-220.

<sup>14</sup> Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, Fu S, Gao L, Cheng Z, Lu Q, Hu Y, Luo G, Wang K, Lu Y, Li H, Wang S, Ruan S, Yang C, Mei C, Wang Y, Ding D, Wu F, Tang X, Ye X, Ye Y, Liu B, Yang J, Yin W, Wang A, Fan G, Zhou F, Liu Z, Gu X, Xu J, Shang L, Zhang Y, Cao L, Guo T, Wan Y, Qin H, Jiang Y, Jaki T, Hayden FG, Horby PW, Cao B, Wang C. 2020. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet*. 395:1569-1578. Erratum in: *Lancet*. 395:1694.

<sup>15</sup> Spinner CD, Gottlieb RL, Criner GJ, Arribas López JR, Cattelan AM, Soriano Viladomiu A, Ogbuagu O, Malhotra P, Mullane KM, Castagna A, Chai LYA, Roestenberg M, Tsang OTY, Bernasconi E, Le Turnier P, Chang SC, SenGupta D, Hyland RH, Osinusi AO, Cao H, Blair C, Wang H, Gaggar A, Brainard DM, McPhail MJ, Bhagani S, Ahn MY, Sanyal AJ, Huhn G, Marty FM; GS-US-540-5774 Investigators. 2020. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. *JAMA*. 324:1048-1057.

<sup>16</sup> Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, Marconi VC, Ruiz-Palacios GM, Hsieh L, Kline S, Tapson V, Iovine NM, Jain MK, Sweeney DA, El Sahly HM, Branche AR, Regalado Pineda J, Lye DC, Sandkovsky U, Luetkemeyer AF, Cohen SH, Finberg RW, Jackson PEH, Taiwo B, Paules CI, Arguinchona H, Erdmann N, Ahuja N, Frank M, Oh MD, Kim ES, Tan SY, Mularski RA, Nielsen H, Ponce PO, Taylor BS, Larson L, Roupheal NG, Saklawi Y, Cantos VD, Ko ER, Engemann JJ, Amin AN, Watanabe M, Billings J, Elie MC, Davey RT, Burgess TH, Ferreira J, Green M, Makowski M, Cardoso A, de Bono S, Bonnett T, Proschan M, Deye GA, Dempsey W, Nayak SU, Dodd LE, Beigel JH; ACTT-2 Study Group Members. 2021. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. *N Engl J Med*. 384:795-807.

<sup>17</sup> ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS. Acute respiratory distress syndrome: the Berlin Definition. 2012. *JAMA*. 307:2526-33.

---

<sup>18</sup> Rajendram P, Sacha GL, Mehkri O, Wang X, Han X, Vachharajani V, Duggal A. 2021. Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis. *Crit Care Explor.* 3:e0327